Conference Coverage

Study outlines risk factors for solid organ cancers after liver transplantation

View on the News

What is driving the risk?

The devil is in the details of this study. The incidence of solid organ tumors being high in the immunosuppressed population is well known, well documented. The difficulty is getting at what is driving that risk.

Lots of things have changed in immunosuppressive therapy over the last 20-25-years. The authors give us a snapshot, but they weren’t able to tell us whether the changes in immunosuppression had any impact on cancer risk, especially in regard to specific types of cancers.

Dr. Darius Mirza of the University of Birmingham, England, was the session cochair at the meeting. He made his remarks in an interview after the session and declared having no relevant conflicts of interest.


 

AT THE 2014 WORLD TRANSPLANT CONGRESS

References

SAN FRANCISCO – The indication for liver transplant, the selection of immunosuppression therapy, and smoking status influence the long-term risk of new solid organ malignancies after liver transplantation, Dr. Sebastian Rademacher reported at the 2014 World Transplant Congress.

Multivariate analysis showed that recipients’ risk of a new solid organ cancer was elevated for those who had a history of smoking (1.89). Risk was reduced for recipients who received tacrolimus, compared with cyclosporine A (0.56), and for patients who had primary biliary cirrhosis/primary sclerosing cholangitis (0.47) or hepatitis C infection (0.21) as the indication for transplantation.

"I think we have to reoptimize and reevaluate the currently used immunosuppressive regimens," Dr. Rademacher said. "We have to adapt cancer surveillance programs for high-risk patients. Further studies into surveillance protocols and surrogate markers and long-term outcomes are recommended."

Researchers led by Dr. Rademacher, a surgeon at the Campus Virchow Clinic, Charité, Berlin, retrospectively studied 1,179 consecutive adults who underwent liver transplantation between 1988 and 2002 and had follow-up evaluations until 2013. Patients were 47 years old, on average, at the time of transplantation, and the median follow-up was 13.3 years.

Their 20-year cumulative incidence of solid organ cancers was 14%, he reported at the congress, which was sponsored by the American Society of Transplant Surgeons. The mean age at cancer diagnosis was 56 years.

The researchers used age- and sex-matched individuals from the German general population for comparison. The standardized incidence ratio in transplant recipients was 1.2 for breast cancer, 9.4 for cancer of the oropharynx and larynx, 1.7 for cancers of the colon and rectum, 3.0 for lung cancer, 3.9 for esophageal and stomach cancers, 4.5 for kidney and bladder cancers, and 4.6 for cancers of the female genitourinary system.

"We tried to evaluate the different immunosuppressive regimens and, over time, we had, I think, 27 different primary regimens," Dr. Rademacher said. Steroid-free regimens and low-dose steroid were part of that consideration, "but we segregated them out. For the five most frequent regimens, there was no significance. We assessed immunosuppressive regimens given over at least 2 years, but there was no difference between the regimens. Also, the trough levels of tacrolimus did not have any significant influence," he said.

The investigators did not have data on cumulative immunosuppression or mTOR [mammalian target of rapamycin] inhibitors, which were introduced late in the study period, according to Dr. Rademacher, who disclosed no relevant conflicts of interest. A surrogate marker of immunosuppression, rejection frequency, did not significantly predict the development of solid organ malignancies.

Recommended Reading

Long-term benefits shown after gastric banding
MDedge Internal Medicine
Gut bacteria populations may predict colon cancers
MDedge Internal Medicine
Vaginal bowel control device shown safe, effective in pivotal trial
MDedge Internal Medicine
Flexible sigmoidoscopy screening reduces colorectal cancer, mortality
MDedge Internal Medicine
Medical consultation rates for surgical cases vary
MDedge Internal Medicine
Benefits outweigh harms of aspirin therapy
MDedge Internal Medicine
FDA okays DNA stool test for CRC screening; Medicare considers coverage
MDedge Internal Medicine
Unnecessary cancer screening 'substantial' in U.S.
MDedge Internal Medicine
Statins associated with significant decrease in risk of hepatocellular carcinoma
MDedge Internal Medicine
Typical risk factors don’t always red-flag coronary disease in IBD patients
MDedge Internal Medicine